Tumor-priming CD8+ natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma
TPNC represents a novel cytotoxic lymphocyte product generated through tumor-driven priming. Their dual recognition capacity, functional versatility, and favorable safety profile highlight their potential as a scalable and personalized immunotherapy platform for hematologic malignancies.
Authors
- J.H. Lee (ORCID: https://orcid.org/0009-0009-2676-4619)
- Jeong‐a Kim (ORCID: https://orcid.org/0000-0003-4674-4606)
- Kyeong‐Hee Kim (ORCID: https://orcid.org/0000-0002-6694-4296)
- Eun‐Jeong Choi (ORCID: https://orcid.org/0000-0001-7283-7887)
- Bohwa Han (ORCID: https://orcid.org/0000-0003-3016-0358)
- Dana Jung
- Duck Cho (ORCID: https://orcid.org/0000-0001-6861-3282)
- Seok-Ho Kim (ORCID: https://orcid.org/0000-0002-2067-6257)
- Sung Yong Oh (ORCID: https://orcid.org/0000-0002-8321-4113)
- Kyungsoo Ha (ORCID: https://orcid.org/0009-0000-5592-3556)
- Jihoon Kim (ORCID: https://orcid.org/0000-0002-2573-4866)
- Ji Hyun Lee (ORCID: https://orcid.org/0000-0003-2341-4911)
- Sung-Hyun Kim (ORCID: https://orcid.org/0000-0002-7596-3886)
- Junsang Doh
Institutions
- Seoul National University (KR)
- Samsung Medical Center (KR)
- Osong Medical Innovation Foundation (KR)
- Dong-A University (KR)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1186/s40164-025-00707-7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Dong-A University
- National Research Foundation of Korea
- Ministry of Science and ICT, South Korea